Ad
Ad
Ad
Ad
© ams Business | December 23, 2020

ams and Senova start production line for antibody digital rapid tests

ams and Senova, a manufacturer of in-vitro diagnostic medical devices based in Germany, have successfully opened a production line for lateral flow tests which will be used to detect antibodies from the Covid-19 (SARS-CoV-2) virus.

In Weimar, Thuringia, and under strict Covid-19 social distancing, ams and Senova opened the line and congratulated the teams who worked hard to bring the idea to production in less than nine months. A specifically developed sensor module, based on ams’ AS7341L sensor, allows spectrally resolved sensitive read-out of lateral flow immune assays, and the data will be sent to a medical certified cloud. The device, using lateral flow technology coupled with a spectral sensor, enables a read-out that is accurate, cost effective, quantitative, and provides an objective result which requires no user interpretation. Through using the Senova GreenLight platform, the test kit can be readily applied in doctor’s offices and other point-of-care situations, the companies explains in a press release. Antibody testing remains essential in the fight against the Covid-19 (SARS-CoV-2) pandemic. It is expected, that people will need several antibody tests when the vaccines are supplied. Before a vaccine is administered, it is important to know the presence of antibodies in the blood. In addition, lateral flow tests for antibodies can be used to check the need for a vaccine and the effectiveness over time. “I am very proud of the achievement ams and Senova have reached together. Moving from concept to volume production in less than nine months shows the quality of our partnership and the capabilities of both companies. Thank you to the teams from ams and Senova who are involved in this exciting innovation,” says Thomas Stockmeier, COO of ams AG, in the press release. “This technology is important to the population right now. With fast, accurate point-of-care testing available we hope to enable medical personnel to implement vaccinations faster and more exactly.” “This is the type of co-operation which is designed to make a positive impact. The teams have worked together highly constructively and pushed each other to achieve excellence in a short period of time,” adds Hans Soeffing, CEO of Senova. “Drawing on our deep expertise, our Senova team has pushed hard to make the Senova GreenLight available for this solution.”
Ad
Ad
Load more news
January 22 2021 10:25 am V18.15.15-1